Analysis of Pivotal Study Data Showed Routine Prevention of Hereditary Angioedema (HAE) Attacks with Cinryze® (C1 esterase inhibitor [human]) Resulted in Improved Health-Related Quality of Life Outcomes Compared to Acute Therapy with C1 Inhibitor While On Placebo

- Data presented at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting -

Nov 12, 2013, 08:00 ET from ViroPharma Incorporated